Amazon and GoodRx Target Prescription Subscribers as US Health Coverage Slips

Amazon and GoodRx are expanding their prescription and healthcare subscription businesses as more Americans face rising medical costs, higher deductibles and gaps in health insurance coverage.

The shift is creating an emerging opportunity for companies that can offer consumers predictable prices for common medicines and healthcare services without requiring traditional insurance for every transaction.

Amazon’s RxPass costs Prime members $5 a month for eligible prescription medicines, while GoodRx has expanded into subscription-based healthcare through its GoodRx Companion program. The companies are targeting consumers who are uninsured, underinsured or simply find that paying cash for certain prescriptions can be cheaper than using insurance.

For investors, the development highlights a broader change in the U.S. healthcare market: prescription affordability is becoming a direct consumer-business opportunity, creating room for technology companies to compete alongside pharmacies, insurers and pharmacy-benefit managers.

Why Prescription Subscriptions Are Gaining Attention

Traditional health insurance does not necessarily mean every prescription is inexpensive.

Consumers can face deductibles, copayments and other out-of-pocket costs. High-deductible plans can be particularly important because patients may have to pay more themselves before insurance coverage becomes more substantial.

At the same time, the number of Americans relying on comprehensive health coverage is under pressure. Reuters reported that nearly 3 million people exited Affordable Care Act marketplace plans in 2026 amid higher premiums following the expiration of enhanced pandemic-era subsidies.

That does not mean these consumers have all become completely uninsured. Some have shifted to other forms of coverage, while others are paying more out of pocket or using alternative arrangements.

The result is a larger market for services that help consumers compare prescription prices and reduce the immediate cost of routine healthcare.

Amazon's RxPass Is Becoming a Larger Pharmacy Strategy

Amazon's prescription business is built around its broader Prime ecosystem.

RxPass, an Amazon Pharmacy benefit, allows eligible Prime members to obtain multiple qualifying medications for a single $5 monthly subscription. Amazon says the program is designed for people who may spend more than $5 per month on eligible medicines, including consumers paying out of pocket.

According to Reuters, the RxPass user base has tripled since its launch in 2023, with more than 70% of users taking three or more medications. Amazon offers roughly 50 generic medicines through the subscription, although the U.S. market contains tens of thousands of approved prescription drugs.

That limitation is important.

RxPass is not a replacement for the entire U.S. prescription market. Instead, it can be viewed as a targeted benefit for consumers who regularly take certain generic medicines.

Amazon also continues to operate Amazon Pharmacy outside the RxPass model. The company says Amazon Pharmacy accepts most insurance plans and allows customers to compare insurance copays with cash prices.

That gives Amazon several ways to capture pharmacy spending rather than relying on a single subscription product.

GoodRx Is Moving Beyond Prescription Coupons

GoodRx has historically been known primarily for helping consumers compare prescription prices and access discounts.

The company is now trying to build a broader recurring-revenue healthcare model.

In May 2026, GoodRx launched GoodRx Companion, a $14.99-a-month subscription that combines free and low-cost generic medications with online care visits and savings on dental, vision, laboratory and imaging services.

In September, GoodRx expanded the concept with a Companion Family Plan priced at $24.99 a month. The plan covers a primary member and up to four dependents and includes access to more than 250 generic medications along with savings on healthcare services.

The company's strategy is therefore broader than simply selling prescription discounts. It is attempting to turn medication savings into a recurring healthcare relationship.

GoodRx's Subscription Revenue Is Already Growing

GoodRx's financial results provide evidence that the subscription strategy is gaining traction.

For the second quarter of 2026, GoodRx reported total revenue of $200.4 million, down 1% from a year earlier. However, subscription revenue increased 39% to $28.5 million from $20.5 million.

The contrast is significant.

Prescription transaction revenue declined 26% year over year to $106.4 million, while subscription revenue grew strongly. GoodRx said the decline in transaction revenue reflected factors including changes in the retail pharmacy landscape and deliberate investment shifts toward its newer subscription offerings.

The company also reported a 76% increase in Pharma Direct revenue to $61.6 million, helped by growth in programs providing access to certain medicines, including GLP-1 treatments.

GoodRx raised its full-year 2026 revenue guidance to $790 million-$805 million and adjusted EBITDA guidance to $240 million-$250 million.

This makes subscriptions more than a side experiment for GoodRx. They are becoming part of its strategy for creating more predictable and diversified revenue.

Why Amazon and GoodRx Are Different

Although both companies are benefiting from demand for lower-cost healthcare, their business models are not identical.

Amazon has a massive consumer ecosystem through Prime, Amazon Pharmacy and its broader retail platform. RxPass can therefore strengthen customer engagement with an existing membership rather than functioning purely as a standalone healthcare business.

GoodRx, meanwhile, is more directly focused on medication affordability and healthcare savings. Its subscription expansion gives the company a way to move from one-time prescription searches toward recurring relationships with consumers.

That distinction matters for investors.

For Amazon, pharmacy subscriptions are relatively small compared with its overall business. Reuters estimates Amazon's 2026 revenue at around $828 billion, meaning RxPass is currently more strategically important than financially transformative.

For GoodRx, however, subscription growth can have a much more visible effect on the company's revenue mix and long-term business model.

The Opportunity Goes Beyond Uninsured Consumers

It would be too simple to describe these services as products only for people without insurance.

Amazon explicitly markets RxPass to Prime members who may be paying out of pocket, while Amazon Pharmacy also works with insurance.

GoodRx likewise says its discounts can be used by people who have insurance, although its discounts cannot be combined with insurance or government programs such as Medicare and Medicaid. GoodRx is not insurance.

That creates a wider potential customer base.

A consumer might have health insurance but discover that paying the cash price for a particular generic medicine is cheaper than using the insurance benefit. In that situation, a prescription savings platform can still provide value.

Risks for Amazon, GoodRx and the Healthcare Model

The opportunity also comes with limitations.

First, prescription subscriptions cover only a portion of healthcare spending. They do not replace comprehensive health insurance, particularly for hospitalization, major surgery, expensive specialty drugs or serious medical conditions.

Second, competition is increasing. Other companies, including Mark Cuban's Cost Plus Drugs and newer digital-health businesses, are also attempting to reduce prescription costs or provide alternative healthcare models.

Third, drug availability matters. Amazon's RxPass covers a relatively limited selection of medicines compared with the broader U.S. prescription market. GoodRx has a wider selection through its platform, but discounts vary by medication and participating pharmacy.

Finally, healthcare is highly regulated. Changes involving insurance, pharmacy-benefit managers, drug pricing, Medicare, Medicaid and prescription rules can materially affect the economics of these businesses.

What Investors Should Watch

The next stage of the story will be whether prescription subscriptions can evolve from a cost-saving tool into durable recurring businesses.

For Amazon, investors can monitor RxPass adoption, Amazon Pharmacy usage and whether pharmacy services strengthen Prime engagement.

For GoodRx, subscription revenue growth, subscriber numbers, margins and the performance of Companion will be particularly important. Investors should also watch whether rising subscription revenue can offset pressure in GoodRx's traditional prescription transaction business.

The broader healthcare market is another important indicator. Changes in insurance enrollment, premiums, deductibles and out-of-pocket spending could influence demand for cash-pay prescription solutions.

At the same time, investors should avoid assuming that declining insurance coverage automatically translates into unlimited growth for prescription-subscription companies. Consumers may respond to higher healthcare costs in many different ways, including switching plans, delaying care or reducing medication spending.

Conclusion

Amazon and GoodRx are positioning prescription subscriptions as an alternative way for U.S. consumers to manage everyday healthcare costs at a time when insurance affordability and coverage are under pressure.

Amazon's RxPass is expanding within the Prime ecosystem, while GoodRx is building a broader subscription model around medicines and routine healthcare services. GoodRx's 39% year-over-year subscription revenue growth in the second quarter shows that the model is already becoming financially meaningful for the company.

For investors, the key issue is not simply whether more Americans seek cheaper prescriptions. It is whether Amazon and GoodRx can turn that demand into sustainable, recurring customer relationships while managing competition, regulation and the limits of subscription-based healthcare.

Follow AIViralHub for more updates on U.S. markets, healthcare businesses, technology companies and global investment trends.

This article is for informational and educational purposes only and should not be considered investment advice.